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INTRODUCTION 
Chronic Kidney Disease (CKD) and Cardiovascular Disease 
(CVD) have been inextricably linked since the earliest days of 
chronic dialysis. Several statistics accrued since that time attest to 
the impact of cardiovascular disease in renal patients. 
Approximately one half of all deaths in end stage renal disease 
patients are attributable to cardiovascular disease, a proportion 
that is remarkably similar throughout the world. Several factors are 
thought to contribute to this high burden of cardiac disease in 
chronic kidney disease patients. First, the prevalence of many 
traditional risk factors for Cardiovascular disease such as diabetes, 
hypertension is higher among CKD patients than in general 
population. Second, several metabolic and hemodynamic 
disturbances that occur and progress in relation to declining renal 
function may modify cardiovascular risk. There is growing evidence 
that, uremia-related risk factors (Anemia, hypercholesterolemia, 
hyperhomocystinemia, divalent ion abnormalities, oxidative stress) 
contribute to the excess burden of cardiovascular disease in chronic 
kidney disease patients. The frequency of fatal and non-fatal 
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cardiovascular events is increased even in the earliest stages of 
chronic kidney disease1. It appears that uremia acts to amplify the 
incidence of fatal ischemic heart disease by a constant factor 
irrespective of the baseline incidence in the general population2.  
When maintenance hemodialysis was introduced by Scribner 
in 1960s, the naïve view prevailed that if one removed uremic toxins 
sufficiently well by dialysis life expectancy would approach that in 
the general population. This view was shattered by a report of 
Lindner et al documenting a strikingly increased rate of death from 
cardiovascular events in hemodialysis patients. Clyde shields, the 
first patient on longterm hemodialysis died of myocardial infarction 
in 1970 aged 50 years, eleven years after starting hemodialysis. The 
burden of cardiac disease in all phases of chronic kidney disease is 
high, and its clinical impact grave. The most frequent clinical 
manifestations are ischemic heart disease and congestive heart 
failure. Ischemic heart disease may be atherosclerotic or non 
atherosclerotic in origin. Congestive heart failure results from 
ischemic heart disease, cardiomyopathy or both. The manifestations 
of uremic cardiomyopathy include concentric left ventricular 
hypertrophy, eccentric left ventricular hypertrophy, Systolic 
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dysfunction and diastolic dysfunction. Risk factors for cardiac 
disease in uremia include age, diabetes-mellitus, hypertension, 
anemia, volume overload, hyperparathyroidism, dyslipidemia and 
perhaps uremia itself. 
Although studies have traditionally focused on the dialysis 
population it has become evident that risk factors for 
cardiovascular disease and their initial consequences to the heart 
already are present during the predialysis phase and persist despite 
significant amelioration in the transplantation phase. Even so, our 
knowledge of these risks and consequences remains far from 
definitive, particularly in the chronic renal insufficiency and 
transplantation phases. Although much data exist on the impact of 
risk factor modification and therapy of congestive heart failure for 
the general population, corresponding trials in the renal population 
have not been done. It is useful to remember that many of the risks 
for cardiovascular diseases are common to both renal and non-renal 
population and the absolute benefit of any intervention tends to 
increase with increasing age.           
In dialysis patients cardiovascular events are the most 
common cause of death3-4. A problem which had to some extent 
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been neglected in the past was cardiac failure as a cause of death. 
Cohort studies indicate that cardiac failure is a common and 
frequently lethal occurrence. Uremic cardiomyopathy presents as 
left ventricular hypertrophy, dilatation and coronary artery disease 
causing diastolic and systolic dysfunction5-6. Doppler derived 
systolic time intervals (STI) are useful indices of myocardial 
electromechanical systolic function7-9. 
The annual incidence of myocardial infarction or angina 
requiring hospitalization among hemodialysis patients is 8% and 
that of heart failure requiring hospitalisation or treatment with 
ultrafiltration is 10%10. Systolic dysfunction disorders that are 
predictive of congestive heart failure can be detectable even before 
the overt decline in left ventricular ejection fraction from the 
Doppler derived STI indices. Appropriate medical treatment or 
adequate ultrafiltration of patients at high risk (Prolonged STI 
index) for developing congestive heart failure, will decrease the 
death rate resulting from congestive heart failure. 
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OBJECTIVES 
The objectives of this controlled study are: 
i)  Evaluate latent systolic dysfunction and  
ii)  Its relation with diastolic dysfunction in hemodialysis 
patients with normal ejection fraction, using Doppler 
derived systolic time intervals. 
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MATERIALS AND METHODS 
Study Population: 
The study population included 25 hemodialysis patients (21 
male, 4 female, mean age 36+ years) and 25 healthy controls 
(15male, 10 female, mean age 37+ 10 years). Patients who were on 
dialysis longer than three months were included in this study. 
Eighteen patients were dialysed thrice weekly and the remaining 
seven patients received dialysis twice weekly. Patients with systolic 
and diastolic blood pressures above 140 and 90mm Hg were 
grouped as hypertensive. According to this classification, 44% of 
patients were hypertensive. The control group comprised of healthy 
normotensive persons with no cardiovascular complaints, normal 
electrocardiogram (ECG) and normal blood chemistries. The 
demographic features and biochemical parameters are shown in 
Table 1 and 2. 
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TABLE-1 Demographic features 
No. of patients 25 
Age (in years) 36+13 
Sex -  Male 
 Female 
21 
4 
Time spent on dialysis (months) 20+6 
Dialysis frequency - Twice/Week 
Thrice/Week 
07 (28%) 
18 (72%) 
Table -2 Biochemical parameters and basic renal disease 
Predialytic blood Urea (mg/dl) 124+33 
Predialytic creatinine (mg/dl) 7.9+1.3 
Urea reduction ratio (URR%) 63.2+6.18 
Haemoglobin (g/dl) 8.7+0.75 
Serum Albumin (g/dl) 3.5+.74 
Primary disease 
Chronic glomerulo nephritis 
Chronic interstitial nephritis 
Others 
 
14 (56%) 
9 (36%) 
2 (8%) 
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INCLUSION AND EXCLUSION CRITERIA 
Hemodialysis patients who were on dialysis longer than three 
months were included in the present study (mean time on dialysis 
20+ 6months) 
Patients with  -  Diabetes mellitus 
-  Acute ischemic syndromes  or  
-  Previous myocardial infarction 
-  Cardiac arrhythmias  
-  Valvular heart diseases  
-  Patients using Angiotensin converting 
 enzyme inhibitors were excluded.  
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ECHOCARDIOGRAPHIC ANALYSIS 
An echocardiographic examination was carried out by using a 
VINGMED CFM 725 echocardiographic system and a 2.5 MHZ 
phase- array transducer. Cardiac rhythm was recorded during the 
examination. Hemodialysis patients were examined using Doppler 
echocardiography the day after hemodialysis. The means of three 
consecutive measurements of the Doppler echocardiographic 
parameters on a good quality recording was taken for each 
parameter. 
Because echocardiography is widely available, simple and 
reproducible it has become the method of choice for assessment of 
left ventricular hypertrophy. Epidemiology studies in non-renal 
population have established that the upper limits of left ventricular 
mass index are 130 grams per m2 for adult men and 102 grams per 
m2 for adult women. Values above these limits indicate left 
ventricular hypertrophy. The patterns of left ventricular 
hypertrophy on echocardiography are concentric hypertrophy, 
Eccentric hypertrophy or asymmetric septal hypertrophy. 
Concentric left ventricular hypertrophy is characterised by a 
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thickened left ventricular wall (>45%) more than 1.2cm during 
diastole with normal ventricular cavity volume. Eccentric left 
ventricular hypertrophy is characterised by increased left 
ventricular mass with increased ventricular cavity volume but the 
relative wall thickness may be normal or low (<45%). The 
calculation of left ventricular mass and volume , not independent of 
patient’s volume status, hence the patient should be as close as 
possible to dry weight. In patients on hemodialysis, it is important 
to standardize the time and conditions of the study in relation to 
the dialysis session. Hence in end stage renal disease patients 
echocardiograms should be obtained the day after the dialysis 
session, with the patient at dry weight or at most, one kilogram 
above dry weight. 
The criterion for left ventricular hypertrophy was left 
ventricular mass index of >134g/m2 for men or > 110g/m2 for 
women11. The left ventricular mass index was calculated by dividing 
the left ventricular mass with body surface area calculated from 
Dubois formula. Pulsed- Doppler flow samples from the mitral 
valve were taken during quiet breathing from a sample volume of 
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0.5cm that was placed at the tip of the mitral valve leaflets in the 
apical four chamber view12.  
Measured parameters were mitral early filling (E wave) Peak 
velocity (PV), mitral late filling (A wave) peak velocity, ratio of E 
wave PV to A wave PV, mitral deceleration slope and deceleration 
time. The isovolumetric relaxation time (IVRT) and isovolumetric 
contraction time were measured (IVCT).  The interval from the end 
of aortic flow or aortic valve closure to the beginning of mitral flow 
or mitral valve opening was taken as the isvovolumetric relaxation 
time. The interval from the end of mitral valve closure to the 
beginning of aortic flow or aortic valve opening was taken as the 
isovolumetric contraction time (IVCT). The presence of abnormal 
left ventricular filling, distensibility and diastolic stiffness or in 
other words diastolic dysfunction was diagnosed according to the 
criteria of working group13. According to this criteria diastolic 
dysfunction is diagnosed when  
Isovolumetric relaxation time > 100 m sec or 
The E/A ratio <1.0   and  
Deceleration time > 220 m sec 
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Systolic dysfunction is defined as an ejection fraction of less 
than 40% indicating impaired myocardial contractility. It often is 
associated with left ventricular dilatation (left ventricular end 
diastolic diameter >5.6cm) defined echocardiographically as left 
ventricular cavity volume index greater than 90ml per m2.  
The left ventricular systolic time intervals were measured by a 
simultaneous recording of cardiac rhythm and aortic flow taken 
during quiet breathing. The pre-ejection period (PEP) was 
measured from the beginning of QRS complex time to the beginning 
of aortic flow. The left ventricular ejection time (LVET) was 
measured from the duration of aortic flow. The ratio of the two 
measurements (PEP/LVET) is the STI index.  
M-MODE PARAMETERS OF HEMODIALYSIS PATIENTS: 
Table-3 Systolic function 
Pre Ejection Period (PEP) 
Left ventricular ejection time (LVET) 
Systolic time interval index (the ratio of the PEP/LVET) 
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Table -4 Diastolic function 
Isovolumetric relaxation time (IVRT)  
‘E’ wave (mitral early filling) 
Peak velocity (PV) 
‘A’ wave (mitral late filling) 
E/A ratio  
Deceleration time (DS) 
Table-5 Criteria of working group 
Systolic dysfunction STI index > 0.04 
Diastolic dysfunction IVRT > 100 msec or 
E/A ratio < 1.0 and 
Deceleration time > 220 msec 
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STATISTICAL ANALYSIS 
The statistical analysis was carried out with the use of a 
statistical package for social sciences (SPSS) for window ver5.0 
Numerical variables were given as mean+SD. Non-numerical 
parameters were given as frequency and percentage. Group analysis 
was performed with the use of an unpaired students t-test. ‘P’ 
values < 0.05 were accepted as significant. 
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RESULTS 
Left ventricular hypertrophy was present in 40% of the 
hemodialysis patients. Left ventricular wall thickness, left 
ventricular diastolic and systolic internal diameters, aortic root, left 
atrial dimensions and left ventricular mass index were increased in 
hemodialysis patients compared with controls. There was no 
difference in the left ventricular ejection fraction (EF 74.08 Vs 
73.72% P= not significant) and fractional shortening (FS 34.92 Vs 
35.64%, P= not significant) between hemodialysis patients and 
controls. 
In assessment of systolic time intervals, both pre- ejection 
period (PEP) and systolic time interval index (STI index) were 
significantly higher in hemodialysis patients compared with 
controls.  
(PEP 69.20m sec Vs 69.20 m sec P= 0.000) (STI index 0.3252 Vs 
0.2716 P=0.000). The difference in left ventricular ejection time 
between hemodialysis patients and controls is not statistically 
significant (LVET 217.60 m sec Vs 231.84 m sec P= 0.224). 
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Prolonged STI index (>0.4) was present in 40% of hemodialysis 
patients. 
In our controlled study, 44% of hemodialysis patients had 
hypertension and left ventricular hypertrophy. Hemodialysis 
patients were compared according to the presence or absence of 
hypertension, to assess whether the differences observed in STI 
parameters will be sustained across these subgroups. The PEP and 
STI indexes were similar between patients with or without 
Hypertension. The STI index (0.3579 in normotensive group Vs 
0.2716 in control group P= 0.045 statistically significant) is still 
higher in the normotensive hemodialysis group compared with 
controls suggests the prolonged systolic parameters are 
independent of the presence of hypertension  or left ventricular 
hypertrophy.  
In the assessment of the diastolic function the isovolumetric 
relaxation time (IVRT) was prolonged >100 msec in six patients 
92.4%), deceleration time >220 m sec in eleven patients (44%) and 
an E/A ratio of less than one in two patients (8%). Two among the 
11 patients with prolonged deceleration time also had prolonged 
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IVRT >100 m sec and E/A ratio less than one. Overall 48% of 
patients had diastolic dysfunction. 
When hemodialysis patients without hypertension were 
compared with controls, the IVRT was still significantly prolonged. 
However, the E/A ratio change did not reach statistical significance. 
Table -6 Comparison of M Mode Parameters of Hemodialysis 
Patients to controls 
Parameters HD Patients Controls P value 
LVEDD mm 50.80 41.92 0.001 
IVS mm 11.12 8.04 0.000 
LVPW mm 10.80 7.80 0.000 
ARD mm 27.60 23.04 0.000 
LAD mm 33.92 23.56 0.000 
EF% 74.08 73.72 NS 
FS% 34.92 35.64 NS 
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Table -7 Comparison of Doppler parameters between HD 
patients and controls 
Parameters HD Patients Controls P value 
PEP msec 69.20 69.20 0.000 
LVET msec 217.60 231.84 0.224 
STI index 0.3252 0.2716 0.000 
E/A ratio 1.630 1.400 0.000 
Deceleration 
Slope msec 
194.00 180.00 0.000 
IVRT msec 84.80 72.28 0.000 
A wave PV 
msec 
0.682 0.624 0.000 
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Table -8 Subgroup Analysis 
Parameters Normotensive 
HD patients 
Hypertensive  
HD patients 
P value 
LVEDD 51.43 50.00 0.536 
IVS 1093 11.36 0.601 
LVPW 10.64 11.00 0.664 
ARD 27.21 28.08 0.607 
LAD 33.21 34.82 0.427 
EF 72.86 75.64 0.155 
FS 34.521 35.445 0.155 
PEP 72.86 64.55 0.148 
LVET 210.00 227.27 0.545 
STI 0.3579 0.2836 0.045 
E/A ratio 1.679 1.569 0.601 
DS 202.86 182.73 0.333 
IVRT 85.71 83.64 0.739 
‘E’ wave 1.106 1.003 0.242 
‘A’ wave 0.647 0.728 0.454 
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The most common features of uremic cardiomyopathy namely 
left ventricular hypertrophy, diastolic dysfunction and systolic 
dysfunction were present in 40%, 24%, and 40% of our 
hemodialysis patients respectively. The diastolic dysfunction and 
latent systolic dysfunction (STI>0.4) were randomly distributed. 
90% of patients with systolic dysfunction had normal IVRT.  
Impaired STI index and prolonged IVRT are independent of the 
presence of hypertension or left ventricular hypertrophy. 90% of 
patients with systolic dysfunction had normal IVRT. 84.4% of 
patients with diastolic dysfunction (IVRT >100 m sec) had normal 
STI index. Combined systolic and diastolic dysfunctions were 
present in 12% of our hemodialysis patients. IVRT is more sensitive 
than E/A ratio in the diagnosis of diastolic dysfunction in our 
hemodialysis patients. 
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REVIEW OF LITERATURE 
Systolic time interval parameters are useful indexes for the 
assessment of myocardial systolic function. Deterioration of STI 
parameters was previously reported in hemodialysis patients20. It 
was also reported that STI index (PEP/LVET) increased after 
hemodialysis, mainly by the decrease in LVET caused by volume 
changes. Therefore, the patients were examined the day after 
hemodialysis in order to exclude the effect of hypervolemia. Left 
ventricular ejection times of hemodialysis patients were similar to 
controls, suggesting that all the patients in our study were 
euvolemic. 
In our study, we have observed that in patients on 
hemodialysis latent systolic and diastolic dysfunction may coexist 
or be present alone and can be diagnosed using non-invasive 
Doppler study even before overt decline in the left ventricular 
ejection fraction. 
In a controlled study,14 echocardiographic findings in 86 
hemodialysis patients and 51 healthy controls were compared for 
STI parameters (PEP, LVET, STI index) and diastolic dysfunction 
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(IVRT, E/A ratio, and deceleration time). The pre-ejection period 
(114+21 Vs. 94+4 msec, P <0.001) and STI index (0.41+0.11 Vs. 
0.34+0.02 (P<0.001) were higher in hemodialysis patients 
compared with controls. Increased STI index and prolonged PEP in 
hemodialysis patients were independent of hypertension and LV 
hypertrophy. Diastolic dysfunction was present in 61% of patients. 
The IVRT were also found to be longer in hemodialysis patients 
compared with controls (97+16 Vs. 75+16 sec P<0.001) 
independent of the presence of hypertension or LV hypertrophy. In 
this study 48% of patients with diastolic dysfunction having an STI 
index within normal limits and the other half of the patients with 
systolic dysfunction having a normal IVRT. The combined systolic 
and diastolic dysfunction was observed in 30% of the patients. 
These authors concluded that systolic and or diastolic dysfunction 
of the myocardium may appear singly or simultaneously and 
deterioration of STI indexes can occur before an overt systolic 
dysfunction (with normal ejection fraction). 
In an another study15 the effects of hemodialysis on left 
ventricular function were studied with the use of externally 
recorded LV systolic time intervals and echocardiography. In this 
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study, ten patients with normal or near-normal predialysis LV 
function and no circulatory congestion were studied. Hemodialysis 
significantly decreased LV ejection time (LVET) from 270+ 9 msec 
to 237+10 msec (P=0.001). No significant change was noted in the 
pre-ejection period (PEP). The STI index (PEP/LVET ratio) 
increased from 0.41+0.05 to 0.45+0.06 (P=<0.05). Hemodialysis 
was also associated with a 17% decrease in LV stroke volume. 
Ejection fraction and fractional shortening did not change 
significantly. Small changes in heart rate and blood pressure were 
insignificant. The authors concluded that post dialysis reduction in 
stroke volume was due primarily to an acute decrease in LV preload 
and dialysis also appears to be associated with a small increase in 
LV contractile state.  
STI offer temporal description7 of the sequential phases of 
cardiac cycle which are influenced physiologically by the same 
variables which affect other measures of LV performance. The STI 
offer a measure of LV function because of extreme sensitivity of this 
variable and ease of its measurement, the STI are well suited for 
studying the effect of pharmacologic agents on heart7. 
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In a study of 11 patients16 with chronic kidney disease and 
hypertension, the responses in the left ventricular systolic time 
intervals following Digoxin administration (0.5 mg intravenously) 
were studied. The control group comprised 11 patients with mild 
essential hypertension. There were no clinical signs of congestive 
heart failure in any of the patients. Authors reported that uremic 
patients had longer pre-ejection period and higher STI index 
compared with controls. Digoxin administration induced a 
reduction in PEP and STI index. These data suggest the presence of 
latent left ventricular systolic dysfunction in the patients with 
chronic kidney disease that improved after administration of 
digoxin. 
Parfrey PS6 studied the outcome and risk factors for LV 
disorders (concentric LVH, LV dilatation with or without LV 
hypertrophy, Systolic dysfunction) in patients with chronic uremia. 
A cohort of 432 ESRD patients who survived at least 6 months had 
an echocardiogram on initiation of dialysis therapy and 
subsequently clinical, laboratory, echocardiography data was 
obtained annually. On initiation of ESRD therapy, 16% of patients 
had systolic dysfunction, 41% concentric LVH, 28% LV dilatation, 
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and only 16% had normal echocardiogram. Median time to 
development of heart failure was 19 months in patients with systolic 
dysfunction, 38 months in patients with concentric LVH and LV 
dilatation. 
The relative risks of heart failure in the three groups were 
significantly worse than in the normal group after adjusting for age, 
diabetes, and ischemic heart disease. Median survival was 38 
months in patients with systolic dysfunction, 48 months in 
concentric LVH, 56 months in LV dilatation and 66 months in the 
normal group. Follow up echocardiography revealed the degree of 
concentric LVH was independently related to hypertension, old age, 
anemia while on dialysis. The degree of LV dilatation was related to 
anemia, IHD, hypertension and hypoalbuminemia while on dialysis. 
The degree of systolic dysfunction was associated with anemia and 
IHD. Authors concluded that manifestations of LV disease are 
frequent in chronic uremia and are associated with high risks of 
heart failure and death. Potentially reversible factors include 
anemia, hypertension, hypoalbuminemia and ischemic heart 
disease. 
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Pre-ejection period consists of two components. The electrical 
component, which begins with the ‘Q’ wave in ECG and represents 
the dispersion of the electrical wave front from endocardium to 
epicardium, and a mechanical contraction component that 
continues until the aortic valve opens. In uremia, both electrical 
and mechanical components of the PEP may be compromised by 
intermyocardiocytic fibrosis caused by an increase in collagen 
content17. 
In an animal experimental study18, the relations between 
hypertrophy, fibrosis, and diastolic performance in early 
experimental hypertension, 18 control dogs, and 12 dogs with 
experimental left ventricular hypertrophy were studied. Diastolic 
function was impaired in dogs with left ventricular hypertrophy as 
indicated by a decrease in Doppler-derived E/A ratio and prolonged 
isovolumetric relaxation time (IVRT). 
At post mortem examination, the hypertensive left ventricle 
weighed significantly more than normal and had greater muscle 
fiber diameter. In contrast, neither percent fibrosis nor fibrotic 
volume was significantly increased in normal dogs. The conclusion 
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from this experimental study was, diastolic dysfunction may exist in 
the setting of hypertrophy and increased myocyte size was 
associated with early diastolic filling abnormalities characteristic of 
the hypertensive left ventricle. 
Abnormal diastolic relaxation is most reliably detected by 
pulsed Doppler measurement of the velocity of the ‘E’ (early, 
passive) and ‘A’ (atrial, active) components of diastolic flow across 
the mitral valve. Decreased left ventricular compliance caused by 
impaired relaxation results in decreased E/A ratio and is frequently 
seen in patients with chronic kidney disease as a result of left 
ventricular hypertrophy. Diastolic dysfunction is associated with an 
increased risk of intradialytic hypotension, as relatively small 
reductions in left atrial filling have marked effects on cardiac 
output. 
Interstitial myocardial fibrosis, a prominent finding in uremia 
had been shown to be more marked in hemodialysis patients 
compared with patients who have diabetes mellitus or essential 
hypertension with similar LV mass24. 
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A recent experimental and clinical study23 suggest (a) that 
cardiac hypertrophy can be dissociated from hypertension and that 
blood pressures may have only a permissive role, (b) that 
experimental uraemia is associated with specific activation of 
pericytes and intermyocardiocytic fibrosis. Cardiac hypertrophy  
not correlated with elevated blood pressure, and 
intermyocardiocytic fibrosis not observed in similarly hypertensive 
non-uraemic patients, have recently been documented in dialysis 
patients. The implications of these findings may be (a) electrical 
instability and predisposition to a sudden cardiac death and (b) 
diastolic cardiac malfunction with impaired LV filling and 
predisposition to dialysis hypotension. Some evidence for the latter 
possibility is provided. 
A paper updates9 the current view on clinical significance of 
systolic time intervals (STI) in estimating the cardiac changes 
associated with hypertension. The following three intervals were 
measured as STI: (1) electromechanical systole (QS2 interval); (2) 
left ventricular ejection time (LVET) and (3) pre-ejection period 
(PEP). Firstly, the influences of changes in heart rate, preload, after 
load and myocardial contractility upon each interval were reviewed; 
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secondly, clinical applications of STI in various types of 
hypertension such as essential hypertension, hypertension with 
angina pectoris and pheochromocytoma were studied. In patients 
with essential hypertension, there was a good positive correlation 
between PEP and left ventricular mass, and a shortening of LVET 
was observed only at the decompensated stage. The changes in STI 
in angina pectoris with or without hypertension were similar and 
were different from those in essential hypertensives. STI in patients 
with pheochromocytoma were characterized by a marked 
shortening of QS2 and LVET with normal PEP. These findings 
indicate the usefulness of STI in detecting cardiac changes in 
various types of hypertension. 
An investigation12 was performed to determine whether 
variables obtained directly from the Doppler left ventricular 
diastolic flow velocity profile provide a reliable estimate of diastolic 
function. Measurements of diastolic flow velocity obtained by 
Doppler echocardiography were compared with volumetric 
measurements of left ventricular diastolic filling determined by 
radionuclide angiography in 12 subjects without cardiac disease and 
in 25 patients with a variety of cardiac diseases. The two methods 
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were in agreement in distinguishing normal from abnormal 
diastolic function in 21(84%) of the 25 patients with cardiac 
disease, identifying diastolic function as normal in 8 and abnormal 
in 13 of these patients. Good correlations were observed between 
certain Doppler variables of left ventricular diastolic flow velocity 
and radionuclide angiographic variables of left ventricular filling. 
The time interval from the aortic closing component of the second 
heart sound to the end of the early diastolic flow velocity peak, 
assessed with Doppler echocardiography, correlated well with the 
time interval from end-systole to the end of rapid filling, assessed 
with radionuclide angiography (r = 0.83). Descent of the Doppler 
early diastolic flow velocity peak correlated well with the 
radionuclide angiographic peak filling rate (r = 0.79). The ratio 
between the heights of the early and late (due to atrial systole) 
peaks of diastolic flow velocity showed good correlation with the 
ratio between percent of left ventricular filling during rapid filling 
and during atrial systole (r 0.76). These findings demonstrate that 
the left ventricular diastolic flow velocity profile obtained with 
Doppler echocardiography compares favorably with radionuclide 
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angiographic variables in the evaluation of left ventricular diastolic 
function. 
London et al19 studied cardiac hypertrophy and arterial 
alterations in end-stage renal disease. He observed Left ventricular 
(LV) hypertrophy is the most common cardiovascular alteration in 
end-stage renal disease patients. LV hypertrophy results from 
chronic flow and pressure overload and combine features of 
concentric and eccentric hypertrophy. The causes of chronic flow 
overload are the presence of AV shunt, salt and water overload, and 
anemia. The pressure overload is related to alterations of physical 
properties of large arteries characterized by an increased arterial 
and aortic stiffness. The systolic function of hypertrophied ventricle 
is preserved, but the diastolic filling is impaired. The ventricular 
hypertrophy progresses over the time on hemodialysis together with 
a progressive worsening of both systolic and diastolic functions.  
Foley RN20 studied clinical and echocardiographic disease in 
patients starting end-stage renal disease therapy. In this study a 
prospective cohort of 433 ESRD patients was followed from the 
start of ESRD therapy for a mean of4l months. Baseline clinical 
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assessment and echocardiography were performed on all patients. 
The major outcome measure was death while on dialysis therapy. 
Clinical manifestations of cardiovascular disease were highly 
prevalent at the start of ESRD therapy: 14% had coronary artery 
disease, 19% angina pectoris, 31% cardiac failure, 7% dysrhythmia 
and 8% peripheral vascular disease. On echocardiography 15% had 
systolic dysfunction, 32% left ventricular dilatation and 74% left 
ventricular hypertrophy. The overall median survival time was 50 
months. Age, diabetes mellitus, cardiac failure, peripheral vascular 
disease and systolic dysfunction independently predicted death in 
all time frames. Coronary artery disease was associated with a 
worse prognosis in patients with cardiac failure at baseline. High 
left ventricular cavity volume and mass index were independently 
associated with death after two years. The independent associations 
of the different echocardiographic abnormalities were: systolic 
dysfunction, older age and coronary artery disease; left ventricular 
dilatation-male gender, anemia, hypocalcemia and 
hyperphosphatemia; left ventricular hypertrophy, older age, female 
gender, wide arterial pulse pressure, low blood urea and 
hypoalbuminemia. Authors conclude that clinical and 
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echocardiographic cardiovascular disease are already present in a 
very high proportion of patients starting ESRD therapy and are 
independent mortality factors. 
A cross sectional study21 was done to see whether cardiac 
morphological and functional abnormalities in uraemic patients are 
determined by high blood pressure or if they are an expression of a 
specific cardiomyopathy in a City general hospital in Italy. In this 
study 35 uraemic patients receiving haemodialysis (17 men, 18 
women; mean age 60.3 (11.2); mean duration of dialysis 52 months) 
were selected from the 64 patients in Venice who were receiving 
dialysis; subjects with diabetes, haemochromatosis, valvar 
dysfunction, regional dyskinesias, and pericarditis were excluded. 
19 control normotensive subjects (6 men and 13 women), matched 
for age. Main outcome measures was echocardiographic 
measurements of left atrium, left ventricular end diastolic and end 
systolic volume, aortic root diameter, posterior wall and 
interventricular septum thickness, left ventricle mass index, and 
ejection fraction in controls and in patients according to whether 
they were normotensive (five men, eight women) or hypertensive 
(12 men, 10 women) on 48 hour ambulatory monitoring; left 
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ventricular diastolic function by Doppler ultrasonography. The 
results of the study was mean systolic and diastolic pressures, 
daytime systolic and diastolic pressures, and night time systolic and 
diastolic pressures were significantly higher in the hypertensive 
patients than in the normotensive patients. The normotensive 
patients had similar blood pressures to the controls. Left 
ventricular mass correlated significantly with the mean diastolic 
pressure and mean night time systolic and diastolic pressures. 
Parathyroid hormone concentrations were similar in the two groups 
of patients. Diastolic relaxation was impaired to the same degree in 
the two groups of patients. Parameters of diastolic function showed 
no relation to left ventricular mass, which was significantly higher 
in the hypertensive than in the normotensive patients. Authors 
concluded uraemia is likely to induce specific changes in the 
relaxation properties of the myocardium. These changes are 
responsible for the impaired diastolic function independently of 
blood pressure, degree of hypertrophy, and metabolic changes, 
which suggests the existence of a specific cardiomyopathy. 
Hypertension remains a determinant of left ventricular mass. 
 41 
The acute effects of hemodialysis on left ventricular (LV) 
function were studied15 with the use of externally recorded LV 
systolic time intervals and echocardiography; 10 patients with 
normal or near-normal predialysis LV function and no circulatory 
congestion were studied. Hemodialysis significantly decreased the 
LV ejection time (LVET) from 270 + 9 ms to 237+10 ms (p=< 
0.001); no significant change was noted in the pre-ejection period 
(PEP). The PEP/LVET ratio increased from 0.41+0.05 to 0.45+0.06 
(p =<0.05). The LV end-diastolic dimension decreased from 5.3+ 
0.3 cm to 4.8+ 0.3 cm (p=<0.001). Fractional shortening and 
ejection fraction did not change significantly, but hemodialysis 
slightly increased mean VCF from 1.2 + 0.1 s-1 to 1.4+ 0.1 s-1 (p 
=<0.005). Hemodialysis was associated with a 17% decrease (87+8 
ml to 72+7 ml; =<than 0.001) in LV stroke volume as calculated 
from echocardiographic data. Small changes in heart rate and blood 
pressure were insignificant. The conclusion of this study was that 
the postdialysis reduction in stroke volume was due primarily to an 
acute decrease in LV preload; dialysis also appears to be associated 
with a small increase in the LV contractile state. 
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In an autopsy study17, Heart was examined in 31 patients with 
uremia not on dialysis, 42 patients on hemodialysis for less than six 
months, 60 patients on hemodialysis for more than six months. 16 
patients after renal transplantation and 11 patients on CAPD. 
Patients with stenosing coronary artery lesions were excluded. 
Diffuse non-coronary intermyocardiocytic fibrosis, assessed by a 
score system in trichrome - stained sections, was found in 91% of 
chronically uremic patients but not in non-hypertensive, non 
diabetic controls. The lesion was present even in non-dialysed 
uremic patients. In dialysed patients, its severity was related to the 
duration of dialysis and it was demonstrable even years after renal 
transplantation. Authors concluded that uremia is an important 
determinant of intermyocardiocytic fibrosis independent of 
hypertension, diabetes, anemia,heart weight and presence or 
absence of dialysis procedure. 
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DISCUSSION 
Uremic patients may present with  
• Left ventricular hypertrophy   
• Congestive heart failure/ Hypervolemia   
• Ischemic heart disease   
• Acquired valvular heart disease   
• Arrhythmias    
RISK FACTORS: 
Cardiovascular causes of death are most prominent in the first 
few years of dialysis and are rare in patients who have been on 
long-term dialysis. Risk factors for cardiovascular disease in 
patients on dialysis are 
• Dyslipidemia  
 – hypercholesterolemia 
– hypertriglyceridemia  
– decreased HDL 
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– increased VLDL increased  
– lipid peroxidation 
• Hyperinsulinemia 
• Hypercoagulability 
• Hypertension 
• Smoking 
• Obesity 
• Sedentary life style 
Other causes specific to uremia: 
• Hyperparathyroidism 
• Phosphate retention 
• Iatrogenic iron overload 
• Inadequate dialysis 
• Hyperhomocystinemia (folate, pyridoxine deficiency) 
• Endothelial dysfunction  
 increased Endothelin  
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 impaired nitric oxide production,  
 hyperhomocystinemia,  
 increased oxidative stress 
• Carbamylation of matrix proteins 
• Decreased anti-oxidant defence. 
Is there a specific uremic cardiomyopathy? 
It has been proposed that uremia per se leads to impaired 
myocardial contractile function. Improvement after institution of 
dialysis or after successful transplantation suggests a dialyzable 
uremic toxin rather than structural alterations or ischemic damage, 
although chronic volume overload may be responsible by causing a 
reversible dilated cardiomyopathy. Improvement in contractile 
function acutely during hemodialysis suggesting that a dialyzable 
uremic toxin has a direct and readily reversible cardiodepressant 
action.  
In the past, cardiac changes in renal failure have commonly 
been ascribed to hypertension and poorly specified toxic effects of 
uremia. In a study by Ritz E et al5 demonstrated that cardiac 
 46 
hypertrophy can be dissociated from hypertension and that blood 
pressure may have only a permissive role and experimental uremia 
is associated with specific activation of pericytes and 
intermyocardiocytic fibrosis. 
In the recent HEMO study, the most common cause of death 
in dialysed patients was ischemic heart disease (20.4%) followed by 
cardiac rhythm disorder (10.4%), cerebrovascular disease (8.6%) 
and infections (7.7%)16. The prospective Canadian study reported 
an incidence of approximately 10% per year for both ischemic heart 
disease and cardiac failure significantly higher than the values seen 
in the general population. The features of uremic cardiomyopathy 
like Left ventricular hypertrophy, diastolic dysfunction and systolic 
dysfunction were detected in 40%, 24% and 40% of our hemodialysis 
patients. These rates were comparable to those reported in previous 
studies17-19. 
LEFT VENTRICULAR HYPERTROPHY:  
In non-renal patients, hypertension and left ventricular 
hypertrophy are closely related, but this relationship is less marked 
in patients with renal failure22.  LV hypertrophy develops in uremic 
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animals despite normalization of blood pressure by administration 
of angiotensin converting enzyme inhibitors, alpha and beta 
blockers or diuretics18.  LV hypertrophy progresses with time on 
dialysis even when patients kept normotensive15. In the study of 
Parfrey6, 71% of non-diabetic dialysis patients without dilated 
cardiomyopathy had LV hypertrophy and in majority of patients 
this progressed over a period of 3-4 years. 
LV hypertrophy is more frequent in early stages of CKD and 
increases progressively. So that it is found in approximately 70% of 
patients starting renal replacement therapy. Initially concentric 
LVH is seen, while in later stages more frequently eccentric LVH 
prevails. LVH tend to be associated with hypertension, anemia, 
high arteriovenous fistula flow and poor control of volume 
overload. At an early stage systolic function is usually normal or 
even increased but evidence of diastolic dysfunction can be found 
even in asymptomatic patients. LVH is not an innocent finding, it is 
an independent predictor of death in dialysis patients. 
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Congestive Heart Failure: 
Ten percent of non-diabetic dialysis patients were found to 
have congestive heart failure15. Nonspecific ancillary findings in 
patients with congestive heart failure are a history of dyspnea, 
edema, cardiomegaly, raised JVP, basal crepitations, pulmonary 
venous hypertension or interstitial edema on chest radiography.  
The most common cause of congestive heart failure in CKD 
patients is ischemic heart disease, but the other factors are 
Hemodynamic factors:  
• Hypertension 
• Hypervolemia 
• Renal Anemia 
• Arteriovenous fistula 
• Acquired valvular heart disease 
• Pericarditis 
Non-hemodynamic factors: 
• Ischemic heart disease 
• Cardiomyopathy 
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• Autonomic dysfunction  
• Excess PTH 
• Aluminium overload 
• Iron overload 
• Myocardial calcification 
• Metabolic acidosis 
• β2 microglobulin amyloidosis 
NON-MODIFIABLE RISK FACTORS: 
Age: 
As with ischemic heart disease, age is an important clinical 
marker of risk for left ventricular hypertrophy in the general 
population, chronic renal disease patients and hemodialysis 
population. 
Sex: 
The role of sex as a risk factor for left ventricular hypertrophy 
and systolic dysfunction is less clear. In a registry-based study24 
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women were found to be more likely to have radiographic 
cardiomegaly or history of congestive heart failure and less likely to 
have ECG or echocardiographic evidence of LVH than men. 
Moreover, female sex was associated with concentric LVH whereas 
male sex was associated with LV dilatation and congestive heart 
failure. 
MODIFIABLE RISK FACTORS: 
Hypertension: 
Hypertension is associated with increased risk of chronic 
kidney disease progression and earlier onset of dialysis. A lower 
than usual target blood pressure (<125/75 mmHg) appears more 
effective in delaying renal decline than usual goal (<140/90) in 
patients with proteinuria more than 1g/day.  In patients on dialysis, 
each 10 mm Hg increment in blood pressure is associated with a 
48% higher risk for development of LVH25. 
Anemia: 
Anemia is associated with LV dilatation and LVH in CKD and 
dialysis patients the relative risk for LVH progression per 10 g/L 
drop is 1.74 in CKD and 1.48 in dialysis patients26. Anemia also is a 
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risk factor for the development of cardiac failure and death in 
dialysis patients. Normalisation of haemoglobin prevent 
progressive LV dilatation in those with normal cardiac volumes at 
baseline but not in patients with established cardiac disease27-28. 
Ischemic heart disease: 
IHD is an important cause of systolic and diastolic 
dysfunction in the general population and in patients on dialysis29. 
CAD may exacerbate ischemia, myocyte attrition and cardiac 
interstitial fibrosis. Myocyte apoptosis, ischemia, and 
neurohormonal activation are thought to contribute myocardial 
dysfunction. 
Hypoalbuminemia: 
Several studies have shown that hypoalbuminemia is a 
powerful predictor of poor outcome in patients with ESRD. 
Hypoalbuminemia is associated with LV dilatation and predisposes 
to cardiac failure30. The mechanism underlying this association are 
unknown. Hypoalbuminemia is associated with a hypercoagulable 
state and therefore may predispose to myocardial infarction and 
ischemic cardiomyopathy. 
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Hypervolemia: 
Salt and water retention is a persistent problem in patients on 
dialysis and is less problematic in early stages of CKD. Blood 
volume correlates directly with LV diameter in patients on 
hemodialysis31 as does the magnitude of interdialytic weight gains. 
LV diameter decreases with volume contraction during 
hemodialysis. By definition, salt and water overload is blood 
volume overload and hence plays a causal role in the development 
of LVH. Keeping the patient’s dry weight optimal can minimise the 
degree of enlargement of the LV5. 
In chronic hemodialysis patients, two groups were identified 
with regard to congestive heart failure. One without a previous 
history of congestive heart failure and the other with a history of 
congestive heart failure at initiation. The independent predictors of 
congestive heart failure at initiation of hemodialysis are age, 
diabetes, ischemic heart disease, systolic dysfunction on baseline 
echocardiogram. In patients free of baseline congestive heart failure 
the predictors of CHF are hypertension, anemia, hypoalbuminemia 
and hypocalcemia. Factors that predispose to volume or flow 
overload (Anemia), pressure overload (Hypertension) and cell 
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death (malnutrition, hyperparathyroidism, hypocalcemia, ischemic 
heart disease) are associated with congestive heart failure in 
dialysis. 
Congestive heart failure may result from systolic dysfunction 
or diastolic dysfunction, the latter occurring because of left 
ventricular concentric or eccentric hypertrophy. Ischemic heart 
disease is an additional independent predictor. Among patients 
with diastolic dysfunction, congestive heart failure results from 
impaired ventricular relaxation. This leads to an exaggerated 
increase in left ventricular end-diastolic pressure for a given 
increase in end diastolic volume. As a result, small excess of salt 
and water can rapidly lead to large increase in left ventricular end-
diastolic pressure, culminating in pulmonary edema. In dilated 
cardiomyopathy, cardiac output is maintained at the expense of an 
increase in both end-diastolic fibre length and end-diastolic 
volume. As ventricular volume increases, failure to achieve 
adequate hypertrophy leads to an increase in wall stress and 
increase in end-diastolic pressure, leading ultimately to pulmonary 
edema.     
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Structural changes in the heart, LVH, cardiac fibrosis and 
myocardial calcification have major impact on cardiac function. 
LVH and cardiac fibrosis are associated with impaired LV 
compliance. This explains why patients with CKD develop heart 
failure so easily when atrial fibrillation supervenes. Reduced LV 
compliance also increases the risk of pulmonary edema during 
hypervolemia because the increase in LV volume during 
hypervolemia cause a more marked rise in LV and diastolic volume 
and pressure which lead to poor tolerance of hypervolemia. 
Congestive heart failure carries a poor prognosis. Acturial survival 
at 2 years is not more than 33% as compared to 80% in patients 
without heart failure15. 
Previous studies14 reported 61% diastolic dysfunction in 61% 
of 86 patients, with nearly 48% of patients with diastolic 
dysfunction having an STI index within normal limits and the 
remaining 52% of patients with systolic dysfunction having a 
normal IVRT. In comparison with this study, we observed, 24% of 
our patients had diastolic dysfunction and 40% had systolic 
dysfunction. These rates were definitely less than to those reported 
in the previous study14. This may be related to the small sample size 
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of our study. We also observed combined systolic and diastolic 
dysfunction in only 12% of our patients which is again very low 
compared to the previous study in which 30% of patients had 
combined systolic and diastolic dysfunction.  
Our study markedly differs from the previous one where only 
half of the patients with systolic or diastolic dysfunction had 
normal IVRT or STI index. But in our study, 90% of patients with 
systolic dysfunction had normal IVRT and 84.4% of patients with 
diastolic dysfunction had normal STI index. However, as in the 
previous study, the impaired STI index, and prolonged IVRT are 
independent of the presence of hypertension or left ventricular 
hypertrophy and IVRT is more sensitive than E/A ratio to diagnose 
diastolic dysfunction.   
In our study, we have observed that in hemodialysis patients, 
latent systolic or diastolic dysfunction may coexist or be present 
alone, and can be diagnosed using non-invasive Doppler study even 
before overt decline in the left ventricular ejection fraction. 
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CONCLUSION 
1. The most common features of uremic cardiomyopathy 
namely left ventricular hypertrophy, diastolic 
dysfunction and systolic dysfunction were present in 
40%, 24%, and 40% of our hemodialysis patients 
respectively. 
2. The diastolic dysfunction and latent systolic dysfunction 
(STI>0.4) were randomly distributed.  
3. Impaired STI index and prolonged Isovolumetric 
relaxation time are independent of the presence of 
hypertension or left ventricular hypertrophy. 
4. 90% of patients with systolic dysfunction had normal 
Isovolumetric relaxation time. 
5. 84.4% of patients with diastolic dysfunction (IVRT >100 
m sec) had normal STI index. 
6. Combined systolic and diastolic dysfunction were 
present in 12% of our hemodialysis patients.  
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7. Isovolumetric relaxation time is more sensitive than E/A 
ratio in the diagnosis of diastolic dysfunction in our 
hemodialysis patients. 
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LIMITATIONS OF OUR STUDY 
• Small sample size. 
• No follow up echocardiogram to assess the increased 
risk of developing heart failure in future. 
• Potential reversible factors like anemia, 
hypoalbuminemia and its effects on latent systolic 
dysfunction are not defined. 
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MASTER CHART 
CRF PATIENTS ON HEMODIALYSIS 
S.No Age Sex 
PrediaIytic 
 urea 
Mg/dl 
Predialytic 
scr  
Mg/dl 
URR 
% 
Hb  
g/dl 
S.Alb 
g/dl 
LVEDD 
mm 
IVS 
mm
LVPW 
mm 
ARD 
mm
LAD 
mm EF% FS% 
PEP  
M.sec IVET STI
E/A 
ratio
DS 
M.sec
IVRT 
M.Sec
E 
wave 
PV 
A 
wave 
PV 
NKD HT/LVH 
1 19 M 189 9.6 47 8.3 5.4 48 13 12 23 35 77 38.8 60 210 0.28 2.4 130 60 1.2 0.5 CGN + 
2 35 M 87 8.5 54 8.8 4 57 13 13 29 40 68 31 40 200 0.2 1.56 220 90   CGN + 
3 19 M 135 8.2 74 8.2 5.6 51 11 11 25 40 75 36.8 50 270 0.14 2.5 130 70 1.4 0.56 CGN + 
4 45 M 145 7.6 68 10.6 5.6 49 12 12 34 38 78 39.6 50 210 0.2 0.96 240 80 0.96 1 CGN + 
5 23 M 165 8.5 69 8.8 5.5 52 13 13 30 36 80 41.4 50 200 0.25 1 120 70 1.3 1.19 CGN + 
6 40 M 157 10.2 66 8.6 4.2 53 8 8 34 34 78 39.8 70 280 0.25 1.4 220 100 1.01 0.71 CGN + 
7 37 M 123 9.3 67 8 3.9 52 12 11 27 34 67 28 80 200 0.4 2.02 130 80 0.87 0.43 CGN + 
8 27 M 153 7.9 69 8 3.5 47 10 10 28 24 67 30 80 340 0.23 1.49 170 90 1 0.67 CGN + 
9 34 M 91 6.7 61 9 3.4 39 10 10 23 27 80 35.5 80 190 0.42 1.2 200 80 0.5 0.4 CGN + 
10 32 M 165 9.2 70 7.8 3.7 45 13 12 28 38 82 43 80 180 0.44 2.1 170 80 0.9 0.42 CGN + 
11 26 F 73 6.8 60 8.8 3.5 59 11 11 37 37 66 30 70 20 0.31 1.2 240 100   CGN - 
12 34 F 72 5.3 52 8.8 3.8 52 12 12 25 35 78 39 80 340 0.23 1.9 220 90 1.15 0.58 CGN - 
13 19 F 60 7.2 58 8 4 42 7 7 25 29 78 38 70 250 0.28 1.4 270 70 1.3 0.9 CGN - 
14 18 F 111 5.6 63 8 3.5 43 7 7 20 25 75 37 80 180 0.44 1.4 160 60 1.2 0.83 CGN - 
15 27 F 117 6.9 65 8.8 3.3 42 8 8 20 25 77 38 80 190 0.42 2.1 170 70 1.2 0.55 VUR - 
16 32 M 90 7.7 66 8.5 4 57 10 9 28 37 80 26 70 220 0.31 0.63 280 120 0.89 1.4 CIN PUV + 
17 33 M 105 9.5 61 8 4.2 53 12 10 31 28 70 33 40 260 0.34 1.3 130 80 0.78 0.58 CIN - 
18 33 M 147 8.5 65 10 4.5 58 12 12 26 39 70 30 70 160 0.43 2.1 150 70 1.2 0.57 CIN - 
19 33 M 153 9 61 9 3.5 55 9 8 28 35 74 35.7 60 160 0.43 1.4 240 90 1.2 0.82 CIN - 
20 28 M 120 6.8 65 9.2 4 58 12 12 30 40 70 30 70 280 0.25 1.6 230 110 0.92 0.57 CIN - 
21 17 M 123 9 59 10.5 4.8 52 12 12 29 37 69 32 70 160 0.43 2.5 130 100 1.29 0.5 CIN - 
22 31 M 147 10.1 65 9.4 3.3 48 13 13 30 33 75 38 90 320 0.28 2.3 190 90 1.1 0.46 CIN - 
23 29 M 123 6.9 59 9.5 3.8 48 14 14 26 33 75 36.8 90 260 0.34 1.4 260 100 0.92 0.62 CIN - 
24 23 M 92 6.4 67 8.8 3.5 55 13 12 24 35 69 29.8 80 200 0.4 1.4 250 90 1.09 0.76 CIN - 
25 26 M 157 8.5 70 8.4 3.3 55 11 11 30 34 74 36 70 160 0.43 1.5 200 80 1.03 0.67 CIN - 
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HEALTHY CONTROLS 
S.No Age Sex Urea mg/dl 
Scr 
mg/dl 
Hb 
(g/dl) 
S.Alb 
(g/dl)
LVEDD 
mm 
IVS 
mm
LVPW 
mm 
ARD 
mm
LAD
 mm EF % FS %
PEP 
m.Sec IVET STI
E/A 
ratio
DS 
M.sec
IVRT 
M.Sec
E 
wave 
PV 
A 
wave 
PV 
1 30 F 20 0.6 14 6 42 8 7 23 23 75 35 68 280 0.24 1.4 180 71 1 0.68 
2 35 M 25 0.8 15 5.5 38 7 7 22 22 74 34 74 280 0.26 1.6 180 68 0.84 0.52 
3 27 M 25 0.8 16 6 45 9 8 24 25 72 38 70 230 0.3 1.5 180 78 0.94 0.62 
4 25 F 20 0.7 13.5 5.3 40 7 8 24 25 75 35 69 240 0.27 1.3 180 68 0.8 0.6 
5 28 F 26 0.8 14 5.5 42 8 7 22 22 70 34 65 230 0.28 1.2 180 78 0.9 0.7 
6 30 M 26 0.8 16 6 43 9 7 23 23 82 38 68 28 0.24 1.2 180 71 0.9 0.7 
7 37 M 25 1 15 5.4 44 8 8 22 25 70 35 74 280 0.26 1.3 180 71 0.8 0.6 
8 35 F 26 0.9 13 5.5 40 7 8 23 23 75 34 70 230 0.3 1.4 180 68 1 0.68 
9 40 F 24 0.9 12.5 5.3 45 9 7 24 24 76 38 69 240 0.28 1.5 180 78 0.94 0.62 
10 42 M 26 0.8 13 5.8 39 8 8 22 25 70 35 65 230 0.28 1.5 180 71 0.94 0.62 
11 32 M 24 0.6 15 6 38 7 7 23 23 75 34 65 230 0.28 1.4 180 68 1 0.68 
12 33 M 25 0.7 14 5.6 40 9 8 24 24 70 38 69 240 0.28 1.3 180 78 0.8 0.6 
13 35 M 26 0.8 13 5.3 42 9 8 24 25 80 35 70 230 0.3 1.2 180 71 0.9 0.7 
14 40 M 25 0.9 14 5.5 43 7 8 23 23 75 34 74 280 0.26 1.6 180 68 0.84 0.52 
15 38 M 24 1 15 5.8 44 8 7 22 24 70 38 68 28 0.24 1.6 180 71 0.84 0.52 
16 40 M 26 1 13 5.8 45 8 7 22 23 72 38 65 230 0.28 1.5 180 78 0.94 0.62 
17 41 M 25 0.9 13.5 5.5 39 7 8 23 22 74 35 69 240 0.28 1.4 180 68 1 0.68 
18 45 M 26 0.8 12.5 5.3 40 9 7 24 24 74 34 70 230 0.3 1.3 180 68 0.8 0.6 
19 30 F 24 0.7 13 5.5 38 8 8 22 25 75 34 74 280 0.26 1.2 180 71 0.9 0.7 
20 23 F 26 0.6 13 5.3 43 7 7 23 24 70 35 68 280 0.24 1.2 180 78 0.9 0.7 
21 30 F 26 0.8 12.5 5.8 44 9 9 24 22 74 38 68 280 0.24 1.3 180 71 0.8 0.6 
22 30 F 24 0.7 12.5 5.5 45 9 9 24 22 73 34 74 280 0.26 1.4 180 68 1 0.68 
23 35 M 24 0.9 14 6 40 7 9 23 22 72 35 70 230 0.3 1.5 180 78 0.94 0.62 
24 37 M 24 1 14 6 44 8 9 22 24 75 35 69 240 0.28 1.6 180 71 0.84 0.52 
25 23 F 25 0.8 14 6 45 9 9 24 25 75 38 65 230 0.28 1.6 180 78 0.84 0.52 
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ABBREVIATIONS 
ARD - Aortic Root Diameter 
AVS -  Arterio Venous Shunt 
CKD - Chronic Kidney Disease 
CVD - Cardiovascular Disease 
CAD - Coronary Artery Disease 
DS - Deceleration slope  
ECG - Electrocardiogram 
ECHO - Echocardiogram  
ESRD - End stage renal disease 
EF - Ejection Fraction 
FS - Fractional Shortening 
HDL - High density lipoprotein 
IVRT - Isovolumetric relaxation time 
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IVS - Interventricular Septum 
IHD - Ischemic heart disease 
LVET - Left ventricular ejection time 
LVPW - Left ventricular posterior wall  
LAD - Left atrial diameter 
LVEDD - Left ventricular end diastolic 
diameter  
LVH - Left ventricular hypertrophy 
PEP - Pre ejection period 
PTH - Parathyroid hormone 
SD                                 -        Standard deviation 
STI - Systolic Time interval 
URR - Urea reduction rate 
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